Bay Street News, May, 2020

Phase 3 results comparing tislelizumab plus chemotherapy to chemotherapy alone met its primary endpointCompany to host investor conference call and […]

KEAPSAKE is a planned Phase 2 randomized trial exploring telaglenastat with standard of care in first-line treatment of patients with […]

CINCINNATI, May 29, 2020 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today that Jack Kenny, Chief Executive Officer, […]

Dosing has progressed through first five cohorts up to 4 mg/kg dose levelStrong safety profile, with no dose-limiting toxicities observedMonotherapy […]

VANCOUVER, British Columbia, May 29, 2020 (GLOBE NEWSWIRE) — Conifex Timber Inc. (“Conifex”) (TSX: CFF) announced today that it will […]

BURLINGTON, Ontario, May 29, 2020 (GLOBE NEWSWIRE) — Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), a Canadian Life […]

VANCOUVER, British Columbia, May 29, 2020 (GLOBE NEWSWIRE) — SouthGobi Resources Ltd. (TSX: SGQ, HK: 1878) (“SouthGobi” or the “Company”) […]

– Data continue to show encouraging clinical activity alongside tolerable safety to deliver a potentially highly differentiated product profile –Conference […]

MONTREAL, May 29, 2020 (GLOBE NEWSWIRE) — Mr. Michael Mueller, Chair of the Board of Directors of Laurentian Bank of […]

MONTREAL, May 29, 2020 (GLOBE NEWSWIRE) — At its meeting held on May 28, 2020, given the highly uncertain economic […]